Last reviewed · How we verify

Kedrion IVIG 10% — Competitive Intelligence Brief

Kedrion IVIG 10% (Kedrion IVIG 10%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous immunoglobulin (IVIG). Area: Immunology.

phase 3 Intravenous immunoglobulin (IVIG) Multiple (polyvalent IgG; Fc receptors; complement system) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Kedrion IVIG 10% (Kedrion IVIG 10%) — Kedrion S.p.A.. Kedrion IVIG 10% is an intravenous immunoglobulin preparation that provides passive immunity by supplying pooled human antibodies to modulate immune responses and neutralize pathogens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Kedrion IVIG 10% TARGET Kedrion IVIG 10% Kedrion S.p.A. phase 3 Intravenous immunoglobulin (IVIG) Multiple (polyvalent IgG; Fc receptors; complement system)
PRIVIGEN (CSL Behring) PRIVIGEN (CSL Behring) Hospices Civils de Lyon marketed Intravenous immunoglobulin (IVIg) Fc receptors, complement system, pathogenic antigens and antibodies
Gammaplex (5%) Gammaplex (5%) Bio Products Laboratory marketed Intravenous immunoglobulin (IVIG) Fc receptors and complement system (indirect mechanism via antibody delivery)
Flebogamma 5% DIF Flebogamma 5% DIF Instituto Grifols, S.A. marketed Intravenous immunoglobulin (IVIG) Fc receptors, pathogenic antigens and antibodies
Asceniv™ Asceniv™ ADMA Biologics, Inc. marketed Intravenous immunoglobulin (IVIG) Polyclonal immunoglobulins (IgG)
IgPro IgPro CSL Behring marketed Intravenous immunoglobulin (IVIG) Multiple pathogenic antigens (polyvalent)
IntragamP IntragamP CSL Limited phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antibodies

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous immunoglobulin (IVIG) class)

  1. CSL Limited · 4 drugs in this class
  2. Instituto Grifols, S.A. · 2 drugs in this class
  3. Bio Products Laboratory · 2 drugs in this class
  4. ADMA Biologics, Inc. · 2 drugs in this class
  5. Grifols Biologicals, LLC · 1 drug in this class
  6. Grifols Therapeutics LLC · 1 drug in this class
  7. Kedrion S.p.A. · 1 drug in this class
  8. Octapharma · 1 drug in this class
  9. Oslo University Hospital · 1 drug in this class
  10. SK Plasma Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kedrion IVIG 10% — Competitive Intelligence Brief. https://druglandscape.com/ci/kedrion-ivig-10. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: